Mohammad AskarPublic working copy · medical review pending

Cornea and ocular surface · 021

Conjunctival flaps: stabilise the surface and choose the right goal

A vascularised conjunctival cover can support a threatened corneal surface. Decide first whether the priority is infection control, structural integrity, comfort or visual rehabilitation; those aims do not always lead to the same procedure.

Working copy published: 2026-11-06T03:47:16+01:00. Source, translation and medical checks remain open. Limitations are stated in the text and references. Editorial text version: 2026-11-05 18:30 CET.

A nonhealing ulcer or epithelial defect needs a cause-based assessment before a cover is chosen. A conjunctival flap may be temporary or definitive in selected eyes, but it is not a transparent optical graft or a substitute for treating infection or a leaking globe.

Terminology and draft status

Original terms and source questions are retained. Arabic medical translations are working copies; selected WHO UMD entries were inspected; further terms remain provisional. Source, translation and medical approval remain pending.

01Define what the flap should achieve

A conjunctival flap (CF; Konjunktivalschwenklappen) uses the patient’s conjunctiva to cover affected cornea while retaining a vascular connection. Explain it as living cover rather than a replacement transparent cornea; the original Gundersen name remains relevant to total coverage. 1

The intended benefit may be surface stability, reduced discomfort or a quieter eye before another reconstruction. In other eyes, a total flap is the planned definitive procedure when further reconstruction is not anticipated. It is therefore not restricted to one universal last-resort sequence. 1

Refractory ulcers, persistent epithelial defects and threatened corneal integrity are clinical contexts, not interchangeable indications. Establish the underlying disease and visual potential. The decision for a painful eye with limited potential can differ from a clear visual-axis reconstruction in an eye with useful potential. 1 2

Discuss what the cover will obscure and whether later treatment is planned. Surface closure or preserved globe integrity is not proof of normal vision or eradicated infection. Document those outcomes separately rather than calling every attached cover a complete success. 1 2

02Examine the ulcer before selecting the cover

Ask about symptom onset, progression, contact lenses, trauma, previous procedures and current or recent drops. Assess baseline vision, lids and closure, corneal sensation when appropriate, and the ocular surface. A persistent defect may have infectious, neurotrophic, exposure-related or inflammatory contributors that need different treatment. 2 3

At the slit lamp, describe the epithelial defect and infiltrate separately, including location, area, depth and any stromal loss. Assess the anterior chamber and signs of threatened or actual perforation; fluorescein and an appropriate Seidel assessment may be relevant. A larger opaque lesion is not merely a larger epithelial defect. 2 3

When infectious keratitis is suspected, arrange indicated microbiological sampling and organism-directed treatment. Persistent deterioration can require renewed sampling or further diagnostic assessment. Covering the surface does not replace antimicrobial care or establish that an infection has been controlled. 2

Progressive thinning, impending or frank perforation and uncontrolled disease require urgent specialist decisions about structural support and infection control. A flap is one possible selected option, not the universal answer to a leaking or severely thinned cornea. The extent and location of tissue loss can favour adhesive or a corneal graft instead. 1 2 3

03Choose extent and alternatives with the patient

Total and partial conjunctival coverage are different plans. The Gundersen-type total cover and more local coverage should be chosen according to the involved surface, available conjunctiva and intended outcome. Preserve the original total-versus-partial distinction without assuming the smaller procedure suits every eye. 1 4 5

Alternatives include cause-directed surface care, amniotic membrane, tarsorrhaphy, tissue adhesive and selected lamellar or penetrating keratoplasty. They do not all serve the same purpose: epithelial support, exposure protection, sealing and replacing damaged stroma are different tasks. Compare the relevant alternatives for this eye rather than listing them as interchangeable treatments. 1 2

Infection is not a reason to assume that every flap is prohibited, and refractory infection is not a reason to cover every ulcer immediately. The AAO describes selected use after failed medical care, while a small trial included resistant infectious ulcers. Neither establishes a standard recipe for all organisms or large perforations. 1 2 4

Explain the expected appearance, covered visual axis, remaining visual potential, possible further treatment and need for continued review. Agree whether the immediate goal is comfort, maintaining the globe or preparation for later reconstruction. Do not present anatomical closure as a promise of useful visual recovery. 1 2

04Plan the technique without inventing a first step

A described bipedicle total-flap technique separates conjunctiva from Tenon’s capsule, mobilises it over the cornea and secures it. This is the technique reported in one trial, not a universally complete operating instruction. Preserve the original topics of peritomy and undermining without inferring them from an unfinished sentence. 4

Before operating, reconcile the area to cover, available tissue, infection management, structural stability and later reconstruction. The original question about the first step should begin with that plan, not with a reflex incision. Instrument and suture choices require an actual supported operative method and relevant instructions. 1 2 4

After surgery, assess the cover, ongoing disease, symptoms, globe integrity and whether further treatment is needed. A covered cornea can complicate direct observation; continue specialist surveillance rather than assuming that disappearance from view means resolution. Infection resolution and freedom from further surgery are separate outcomes from epithelial cover. 1 2 5

Review frequency depends on severity and course; severe keratitis or progression can need very close or inpatient care. Give written drop instructions, warning symptoms and a contact route. Do not replace individual early follow-up with a generic long-term visit schedule or tell the patient to stop antimicrobials because a flap is present. 2 3

05Read success rates in their study context

The randomised CF-versus-amniotic-membrane graft (AMG) study included 40 eyes of 40 patients with nonviral infectious keratitis resistant to medical care, with 20 eyes per arm and 6 months of follow-up. The CF arm included 12 fungal, 7 bacterial and 1 Acanthamoeba cases; AMG included 13, 5 and 2 respectively. These were selected severe infections, not every persistent epithelial defect. 4

Success was reported in 18/20 eyes (90%) in each arm. Between-group differences were not significant for success (P=1.0), epithelialisation time (P=.75) or visual improvement (P=.84). Four CF and two AMG eyes were already perforated; three and four respectively had a descemetocele. Those small, imbalanced subgroups do not establish one best treatment for perforation. 4

The complete indexed abstract was read, but the full randomisation, masking, missing-data handling, success definition and protocol were not inspected. A nonsignificant result in a small comparative trial is not proof of equivalence or noninferiority. Its authors also caution that larger perforations may need another procedure; do not turn the observed rate into an individual guarantee. 4

A 2026 retrospective single-centre series reported 9 complete and 12 partial flaps. Success meant infection resolution without further surgery or ongoing antimicrobials: 55.6% versus 66.7%. Final mean acuity was 2.7±0.7 logMAR after complete versus 1.7±1.0 after partial flaps (P=.043). These are different populations and a different success definition from the earlier trial. 5

Larger ulcer area was associated with failure (P=.021). Time-to-resolution comparisons differed: Wilcoxon P=.029 and log-rank P=.053. Small selected groups, confounding by severity, multiple analyses and abstract-only access prevent a causal claim that partial flaps are superior. The two test results should not be collapsed into a single claim of significant faster healing. 5

06Explain the decision and its limits

Present the decision as finding, significance and next step: nonhealing surface or stromal loss, cause and structural threat, then appropriate specialist treatment and surveillance. The summary retains the original three topics of terminology, total-versus-partial definition and operative planning while removing unsupported examiner claims. 1 2 3

The source export contains only a short mixed-language fragment naming conjunctival flaps. It does not establish a regional dialect, a complete surgical instruction or a mandatory first manoeuvre. The exact fragment and all original analytical/table wording remain in the source-history record and immutable snapshot; the recording itself was not inspected.

Use established terminology with a plain explanation and separate a guideline recommendation from a small trial or selected series. Remaining full-source, operative and clinical-language questions must be resolved before medical release. A technically working learning page cannot supply missing evidence or personal review of its medical content. 1 2 6

Explain the decision and its limits
TopicClinical meaningNext step / limit
Conjunctival Flaps / GundersenVascularised corneal cover; total cover is one recognised formExplain healing/comfort/structural goals separately from optical recovery.
Definition: total versus partialExtent is chosen for the diseased surface and goalDo not infer causal superiority from different retrospective groups.
Operative sequence and instrumentsAssessment, source-supported plan and trained executionThe original unfinished phrase does not establish a first incision or a universal technique.
What are the main points when considering a conjunctival flap?

Define the corneal disease and structural threat, assess infection and visual potential, then choose a temporary or definitive cover with relevant alternatives. Total/partial extent, operative planning and follow-up are individual. A short source fragment cannot establish the first surgical step.

Which findings require urgent assessment?

New or worsening visual loss, severe pain, marked inflammation, progressive thinning or suspected leakage/perforation require urgent eye assessment. The original new-field-loss warning remains important even though it is not specific to corneal disease. A recently covered cornea still needs investigation of new deterioration. The original pressure-elevation and suspected neurological-cause warnings also require assessment in their clinical context; they do not define a flap indication.

References and access status

  1. 1
    AAO Corneal Edema and Opacification PPP 2024

    Actual downloaded PDF, selected text P 267 and selected paragraphs P 271–272 read. Full guideline, methods, appendices and actual page images not completely inspected; older 2018 source not used as the current version.

  2. 2
    AAO Bacterial Keratitis PPP 2024

    Actual downloaded PDF, complete diagnosis text P 101–102 and selected treatment/complicated-case/provider text P 110–111 read. Full guideline, methods, appendices and actual page images not completely inspected. Selected flap use does not establish a universal operative recipe.

  3. 3
    DOG/BVA 13 Keratitis,17 August 2011

    All 5 pages of actual extracted PDF text read; historical 2011 guidance, not a current comprehensive flap protocol. Old drug/dose/availability statements are not imported as current instructions.

  4. 4
    Randomised CF versus AMG, PMID 25053758

    Complete indexed abstract read; online 2014, issue 2015. Full publisher article returned 403; main methods, masking, missing-data handling, success definition, protocol and supplements unread. No equivalence margin or confidence interval inferred.

  5. 5
    Retrospective conjunctival-flap series 2026, PMID 41650351

    Complete indexed abstract read; online 2 February 2026, operations 2015–2023. Full report/tables/protocol and detailed follow-up unread. Small selected complete/partial groups, confounding and multiple tests; no causal superiority or pooling with the earlier trial.

  6. 6
    WHO EMRO Unified Medical Dictionary

    Actual English-to-Arabic entries inspected 5 November 2026 for conjunctival flap and selected keratoplasty forms. Other compounds remain working translations; the short original transcript and full recording are not validated by a dictionary. Exact source history is retained separately.